RxDoctor Payments Data

Roger Sullivan, MD

Family Medicine · Charleston, SCNPI 1346534484

Payments from drug & device makers

$10,171in general payments, 2019–2025

Across 508 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Arcutis Biotherapeutics, Inc.$901
  • LEO Pharma Inc.$886
  • Sanofi$771
  • Pfizer$661
  • Sun Pharmaceutical Industries Inc.$550
  • plus $5K from 30 others

What the payments were for

  • Food & beverage$9,80096%
  • Education$3714%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,171 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$790,701
Medicare patients
1,410
Services billed
90,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$293,738
Skyrizi PenRisankizumab-Rzaa12$262,773
Dupixent PenDupilumab52$228,824
OtezlaApremilast17$83,971
RinvoqUpadacitinib11$74,752
Dupixent SyringeDupilumab12$43,922
Clobetasol Propionate371$17,190
Tacrolimus57$7,809
Ketoconazole309$5,482
Hydrocortisone Valerate93$4,218
Tretinoin43$3,554
Fluorouracil46$2,837
Doxycycline Hyclate144$2,651
Minoxidil231$2,650
Triamcinolone Acetonide197$2,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$291$83,97117 claims
AbbVieRinvoq$1,301$74,75211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →